Lower dose of olverembatinib for chronic myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at whether lowering the dose of olverembatinib (from 30 or 40 mg to 20 mg every other day) keeps working well for people with chronic myeloid leukemia who have already had a good response. It aims to see if a lower dose can still control the cancer while possibly reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have chronic myeloid leukemia in the chronic phase and are currently taking olverembatinib (30 mg or 40 mg every other day)
- Before switching to a lower dose, you had at least two tests showing very good response (complete cytogenetic response or BCR::ABL1 ≤ 1%)
- You are willing to switch to a lower dose (20 mg every other day) and follow all study procedures
- You are generally well enough that everyday activities are mostly manageable (ECOG score 0–2)
- You are not pregnant, breastfeeding, or planning to become pregnant during the study, and you do not have an uncontrolled infection or severe medical complications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug olverembatinib alone for people with newly diagnosed chronic phase CML who have not had much prior treatment. It aims to see how well the drug works and what side effects it may cause.
This trial tests a new oral drug, olverembatinib, for people with chronic-phase CML that has not responded well to at least two other TKIs, or who have a specific mutation (T315I). The goal is to see if it can control the leukemia better.
This trial tests a combination of three drugs (olverembatinib, venetoclax, and azacitidine) for people with a fast-growing form of chronic myeloid leukemia (CML) called blast phase. The goal is to see if this treatment can help control the leukemia when it has moved to a more aggressive stage.
This trial tests how a drug called olverembatinib is processed by the body in people with different levels of liver impairment. It looks at how the liver condition affects the drug levels and safety, which may help find the right dose.
This trial tests a new targeted drug, olverembatinib, in adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if this drug can help control the leukemia with manageable side effects.
This trial studies olverembatinib to treat certain blood cancers that have an FGFR1 rearrangement (a specific gene change). It’s for people whose disease is newly diagnosed, has progressed, or has come back, and who can safely take the study medicine and attend follow-up visits.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.